Para pacientes que toman warfarina, se recomienda monitorear el INR con mayor frecuencia al iniciar o ajustar la terapia con GLP-1
Cross-sectional human studies cannot adequately control for potential confounding variables, particularly dietary factors
Ya yakc supplementler, vcudun ya yakm srecini hzlandrmak, metabolizmay desteklemek ve enerji seviyelerini artrmak iin kullanlan besin takviyeleridir
52 In a phase 1b trial done to evaluate the safety, pharmacokinetics and pharmacodynamics of orforglipron in patients with T2DM, orforglipron resulted in significant reductions in HbA1c, fasting blood glucose and body weight, with an adverse event profile consistent with that of other GLP-1RA
Some services specialize in GLP-1 weight loss programs, while others focus more on managing type 2 diabetes through access to endocrinologists or metabolic health experts